Recent Updates
Recently added Catalysts
VNRX Positive Sentiment

Capture-Seq™: Compelling proof-of-concept clinical data. A world first in isolating pure tumor-derived DNA from a liquid biopsy

Wednesday, March 25, 2026 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: Capture-Seq™ represents a significant advancement in liquid biopsy technology, achieving the ability to isolate pure tumor-derived DNA from blood samples. The clinical data presented indicates high accuracy across various cancer types, suggesting its potential to enhance early detection and inform treatment strategies. This innovation could lead to improved patient outcomes in oncology.
Price reaction · baseline $4.022 (2026-03-24 close) · hit pre-market · 5 other VNRX headline(s) in the window, move may be shared
day 0 close
-4.9%
day 1
-4%
day 3
-5.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Breakthrough technology in liquid biopsy.
  • Exceptional accuracy in isolating tumor-derived DNA.
  • Potential to transform early cancer detection and treatment.
  • First-of-its-kind approach in the industry.

Full Press Release Details

Capture-Seq™ is a breakthrough liquid biopsy technology delivering a world-first ability to isolate highly pure tumor-derived DNA from blood. With compelling clinical data showing exceptional accuracy across multiple cancers, it has the potential to transform early detection, treatment decisions, and patient outcomes.

Related Articles

• Press Releases Data Showing the Prognostic Value of its Nu.Q® Cancer Test
• Poster & Publications Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

Data Showing the Prognostic Value of its Nu.Q® Cancer Test

Cytokine-induced chromatin accessibility in whole blood neutrophils links to sepsis transcriptional states

• Share
• Tweet
• Share on Facebook
• Share

Subscribe for Volition product updates .

Or, click here for Investor Updates and press releases .

" * " indicates required fields

Frequently Asked Questions

What is Capture-Seq™?

Capture-Seq™ is a liquid biopsy technology that isolates pure tumor-derived DNA from blood.

What are the benefits of Capture-Seq™?

It offers exceptional accuracy in cancer detection and can improve treatment decisions and patient outcomes.

Is Capture-Seq™ effective across all cancers?

Yes, the clinical data shows high accuracy across multiple cancer types.

What makes Capture-Seq™ unique?

It is the first technology capable of isolating highly pure tumor-derived DNA from liquid biopsies.

ShareAdd on Google
Tags: VNRX Viatris Investor Conferences Healthcare Capture-Seq liquid biopsy tumor-derived DNA cancer detection
Last updated: Mar 25, 2026

Biotech snapshot

Cash runway
$3M liquidity · $2M/mo burn
~1 mo
High dilution risk